GOSS
Gossamer Bio Inc
NASDAQ · Biotechnology
$2.26
-0.18 (-7.19%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 117.35M | 95.94M | 101.30M | 82.00M |
| Net Income | -57,840,914 | 13.15M | 13.02M | 10.81M |
| EPS | — | — | — | — |
| Profit Margin | -49.3% | 13.7% | 12.9% | 13.2% |
| Rev Growth | — | +8.6% | -0.1% | -2.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 227.57M | 246.05M | 242.42M | 231.61M |
| Total Equity | 33.98M | 241.28M | 245.05M | 267.08M |
| D/E Ratio | 6.70 | 1.02 | 0.99 | 0.87 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -46,106,082 | 20.01M | 19.52M | 14.99M |
| Free Cash Flow | — | 11.25M | 11.45M | 12.65M |